Dr. Lucas Mendez, MD
Claim this profileLondon Regional Cancer Program
Area of expertise
Prostate Cancer
Lucas Mendez, MD has run 3 trials for Prostate Cancer.
Endometrial Cancer
Lucas Mendez, MD has run 2 trials for Endometrial Cancer. Some of their research focus areas include:
Affiliated Hospitals
London Regional Cancer Program
London Regional Cancer Program Of The Lawson Health Research Institute
Clinical Trials Lucas Mendez, MD is currently running
Genetic-Based Adjuvant Therapy
for Endometrial Cancer
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Recruiting
1 award
Phase 2
Hypofractionated Radiotherapy
for Cervical Cancer
External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 3 or 4 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. This study investigates the role of shortened external radiotherapy regimen (hypofractionated radiotherapy) by randomizing patients to this experimental regimen versus the standard of care.The purpose of this study is to access the feasibility of patient accrual to this trial in the Canadian setting and to provide an initial evaluation of cancer response and treatment tolerability.
Recruiting
1 award
Phase 2
11 criteria
More about Lucas Mendez, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Lucas Mendez, MD has experience with
- UltraSound-guided Low-dose Rate Brachytherapy
- Concurrent Chemotherapy
- External Beam Radiotherapy (EBRT) + High-dose Rate (HDR) Brachytherapy Experimental
- External Beam Radiotherapy (EBRT) + High-dose Rate (HDR) Brachytherapy Standard Of Care
- Observation
- Vaginal Brachytherapy
Breakdown of trials Lucas Mendez, MD has run
Prostate Cancer
Endometrial Cancer
Cervical Cancer
Circulating Tumor Cells
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lucas Mendez, MD specialize in?
Lucas Mendez, MD focuses on Prostate Cancer and Endometrial Cancer. In particular, much of their work with Prostate Cancer has involved treating patients, or patients who are undergoing treatment.
Is Lucas Mendez, MD currently recruiting for clinical trials?
Yes, Lucas Mendez, MD is currently recruiting for 3 clinical trials in London Ontario. If you're interested in participating, you should apply.
Are there any treatments that Lucas Mendez, MD has studied deeply?
Yes, Lucas Mendez, MD has studied treatments such as UltraSound-guided Low-dose Rate Brachytherapy, Concurrent Chemotherapy, External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental.
What is the best way to schedule an appointment with Lucas Mendez, MD?
Apply for one of the trials that Lucas Mendez, MD is conducting.
What is the office address of Lucas Mendez, MD?
The office of Lucas Mendez, MD is located at: London Regional Cancer Program, London, Ontario N6A 5W9 Canada. This is the address for their practice at the London Regional Cancer Program.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.